Cannabis stock MariMed has a much smaller market cap than Aurora Cannabis but a better position in the U.S. market
Rising just behind Scotts Miracle-Gro and MedMen Enterprises, MariMed is the third-biggest United States-based marijuana stock. The company’s tremendous growth prospects have helped it attain the ranking as the best-performing cannabis stock in the first half of 2018.
MariMed is incredibly well positioned for federal cannabis legalization in the U.S. and to thrive as the marijuana markets in multiple states mature. The company provides professional management services to industry growers. They also assist businesses in obtaining the necessary state licenses and sets them up with operating facilities.
In addition to their behind-the-scenes work in helping marijuana businesses get their start, MariMed fields several cannabis product brands that make edibles, extracts, and vape pens. The company currently markets its products and services in Delaware, Illinois, Nevada, Maryland, and Massachusetts.
In the future, MariMed plans to launch in Florida, Michigan, Ohio, New Jersey, and Pennsylvania. While the company’s prospects are high, the fact remains that there is no guarantee their investment to expand will pay off. Much like MedMen, MariMed has yet to turn a profit.
MariMed could be the best-positioned cannabis company in the U.S. market, but it will not save them from a federal crackdown or other worst-case-scenario events that threaten to crash their big plans.
For now, MariMed is enjoying steadily increasing stock prices as its sales in the five states where it operates continue to skyrocket. Analyst Keith Speights for The Motley Fool recommends MariMed as a solid stock buys over Aurora Cannabis, a stock that currently has a cap ten-times higher than MariMed.
